V
Vaxart, Inc. (VXRT)
OQX – Real vaqt narxi. Valyuta: USD
0.54
-0.00 (-0.84%)
Bozor ochiq: Aug 12, 2026, 11:51 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
OQX – Real vaqt narxi. Valyuta: USD
0.54
-0.00 (-0.84%)
Bozor ochiq: Aug 12, 2026, 11:51 AM EDT
Vaxart, Inc. klinik tadqiqot bosqichidagi biotexnologiya kompaniyasi bo'lib, o'zining vektor-yordamchi-antigen standartlashtirilgan texnologiyasiga asoslangan og'iz orqali qabul qilinadigan rekombinant oqsil vaktsinalarini kashf etadi va ishlab chiqadi. Kompaniyaning mahsulotlar qatoriga norovirusga qarshi vaksina, GI.1 va GII.4 norovirus shtammlari uchun 2-bosqich klinik sinovda bo'lgan bivalent og'iz orqali qabul qilinadigan planshetli vaksina; SARS-CoV-1, SARS-CoV-2 va Yaqin Sharq respirator sindromi koronavirusini davolash uchun 2b-bosqich klinik sinovda bo'lgan COVID-19 vaksinasi; H1N1 grippini davolash uchun 2-bosqich klinik sinovda bo'lgan mavsumiy gripp vaksinasi; va bachadon bo'yni saratoni va bachadon bo'yni oldi saraton lezyonlari uchun HPV-16 va HPV-18 ni nishonga oladigan preklinik bosqichda bo'lgan inson papillomavirusiga qarshi terapevtik vaksina kiradi. Kompaniya Altesa Biosciences, Inc. bilan kapsid-bog'lovchi keng spektrli antiviral Vapendavirni ishlab chiqish va tijoratlashtirish bo'yicha litsenzion kelishuvga ega. Vaxart, Inc. Janubiy San-Fransisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. James F. Cummings M.D. | Chief Medical Officer |
| Dr. Rajesh Kapoor Ph.D. | Senior Vice President of Quality |
| Dr. Sean N. Tucker Ph.D. | Senior VP & Chief Scientific Officer |
| Mr. Edward B. Berg | Senior VP & General Counsel |
| Mr. Jeroen Grasman M.B.A. | CFO, Principal Accounting Officer & Principal Financial Officer |
| Mr. Steven Lo | President, CEO & Director |
| Ms. Laurie Hastings | Senior Vice President of Human Resources |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-06 | 8-K | vxrt20260806_8k.htm |
| 2026-07-28 | 8-K | vxrt20260727_8k.htm |
| 2026-07-17 | 8-K | vxrt20260717_8k.htm |
| 2026-07-07 | 8-K | vxrt20260706_8k.htm |
| 2026-07-06 | DEFA14A | ea0297029-defa14a_vaxart.htm |
| 2026-07-02 | DEFA14A | ea0296966-defa14a_vaxart.htm |
| 2026-07-02 | 8-K | ea0296709-8k_vaxart.htm |
| 2026-07-01 | DEFA14A | ea0296711-defa14a_vaxart.htm |
| 2026-06-26 | DEFA14A | ea029605001ex1.pdf |
| 2026-06-16 | DEFA14A | ea0294896-defa14a_vaxart.htm |